Clinical trialNCT00333476TerminatedPhase 2Interventional

A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

SponsorGenaera CorporationEnrollment140Macular Degeneration

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine in the treatment of AMD.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Alexander Eaton, MD
Retina Health Center
Principal Investigator
clinicaltrials.gov ↗
Charles Garcia, MD
Charles Garcia, MD, P.A.
Principal Investigator
clinicaltrials.gov ↗
Glenn Stoller, MD
Ophthalmic Consultants of Long Island
Principal Investigator
clinicaltrials.gov ↗
Nelson Sabates, MD
Eye Foundation of Kansas City
Principal Investigator
clinicaltrials.gov ↗
Phillip Rosenfeld, MD
Bascom Palmer Eye Institute
Principal Investigator
clinicaltrials.gov ↗
Randy Katz, MD
Florida Eye Microsurgical Institute, Inc.
Principal Investigator
clinicaltrials.gov ↗
Raymond Sjaarda, MD
Retina Specialists
Principal Investigator
clinicaltrials.gov ↗
Steven Rose, MD
Retina Associates of Western New York
Principal Investigator
clinicaltrials.gov ↗
Thomas Ciulla, MD
Midwest Eye Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Florida Eye Microsurgical Institute
Boynton Beach, Florida, United States
Retina Health Center
Fort Meyers, Florida, United States
Bascom Palmer Eye Institute
Miami, Florida, United States
Midwest Eye Institute
Indianapolis, Indiana, United States
Retina Specialists
Towson, Maryland, United States
Eye Foundation of Kansas City
Kansas City, Missouri, United States
Ophthalmic Consultants of Long Island
Long Island City, New York, United States
Retina Associates of Western New York
Rochester, New York, United States
Charles Garcia, Md, P.A.
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MSI-1256F

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2006
Primary completion: —
Completion: —
Last update posted: 28 Nov 2007
Registered enrollment: 140
Registry id: NCT00333476

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.